Detalhe da pesquisa
1.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Cell
; 185(3): 467-484.e15, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081335
2.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729167
3.
The impact of targeted fee increases on the pay disparity between female and male general surgeons in British Columbia.
Can J Surg
; 66(6): E522-E531, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37914209
4.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
5.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
6.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306989
7.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
8.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
9.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702298
10.
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.
Lancet Infect Dis
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621405
11.
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Lancet Infect Dis
; 23(8): 956-964, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37060917
12.
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Vaccine
; 40(35): 5248-5262, 2022 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35715352
13.
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Lancet Microbe
; 3(9): e663-e671, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35907430
14.
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.
Front Immunol
; 13: 795463, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35197971
15.
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
EBioMedicine
; 85: 104298, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36229342
16.
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
EBioMedicine
; 81: 104128, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35779491
17.
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
JCI Insight
; 7(7)2022 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192543
18.
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies.
Vaccines (Basel)
; 9(3)2021 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33809415
19.
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.
Nat Commun
; 12(1): 4636, 2021 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34330906
20.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Nat Commun
; 12(1): 5861, 2021 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34615860